Sandoz Completes JEB SAS Acquisition, Expands Biologics Capabilities

Sandoz , the global leader in affordable medicines, announced the completion of the acquisition of Just-Evotec Biologics EU SAS (JEB SAS) from Evotec SE. The deal includes the Toulouse development and manufacturing site and an indefinite licence to cutting-edge continuous-manufacturing technology for biosimilars.

This milestone fully aligns with the Sandoz biosimilar strategy, expanding in-house drug substance development and manufacturing capabilities and leveraging continuous-manufacturing technology to boost efficiency and scalability. It further positions Sandoz to capitalize on the projected >USD 300 billion global biosimilars LoE market over the next decade¹.

Richard Saynor, CEO of Sandoz, said: “Biosimilars are the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly. This acquisition is a pivotal step toward advancing our ambition to consolidate our position as the undisputed leader in biosimilars. It gives us greater control over our pipeline development and underscores our unwavering commitment to expanding access to high-quality, affordable biologics for millions of patients worldwide.”

The fully automated, high-throughput continuous-manufacturing platform represents a transformative leap in biosimilar production. Sandoz has secured an indefinite license to this cutting-edge technology, which enhances operational efficiency, ensures flexibility and enables cost-effective scalability.

The acquisition complements ongoing investments in Slovenia, reinforcing the Sandoz strategy to build a robust, end-to-end in-house biosimilars network across Europe. By co-locating drug-substance development and manufacturing capabilities and leveraging cutting-edge continuous-manufacturing technology, Sandoz creates operational synergies that support its leadership position in this rapidly growing market. The Slovenian site will focus on large-scale fed-batch drug substance manufacturing, while the Toulouse site will specialize in small-scale continuous manufacturing.